Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.“Evidence continues…
Story updates
10:48:23 AM UTC
SquawkNews
MRK MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SCIBRUNCH THERAPEUTICS FOR SPR2015, AN INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR (DESIGNED TO BLOCK THE KRAS G12D GENE MUTATION THAT CAUSES TUMOURS TO GROW IN CANCERS LIKE PANCREATIC AND COLORECTAL CANCER)